Dimericon Therapeutics AG
DimericonTx is employing a novel peptidic therapeutic modality and a unique discovery engine to tackle hard-to-drug intracellular protein-protein interaction targets. Following a seed round led by AbbVie Ventures and BiomedVC in 2023, Dimericon is progressing a portfolio of preclinical programs in oncology, immunology and inflammation.
Date, time and room information
May 5, 16:15 - 16:30, room Singapore
Category
Emerging biotech company
Title of the presentation
Targeting what’s beyond the reach of small molecules or antibodies
Speaker information
| Name | Position | Institution |
|---|---|---|
| Dr. Ulrich Kessler | CEO | Dimericon Therapeutics AG |
